Showing 151-160 of 7579 results for "".
Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvResearch Highlights Disparities in AD Care
https://practicaldermatology.com/programs/practical-dermatology/research-highlights-disparities-in-ad-care/36472/In this episode of DermwireTV, research on socioeconomic disparities in atopic dermatitis care; new information on guselkumab for scalp psoriasis in diverse skin tones; the impact of air quality on dermatitis; and a C-Suite Chat with Anastasia Georgievskaya, founder of Haut.AI.Journal Club: Height Improvement After Treatment
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-height-improvement-after-treatment/32406/Practical Dermatology Editorial Board member Peter Lio, MD, talks with Amy Paller, MD, about research into patients with severe atopic dermatitis and lower stature achieving significant improvement in height following treatment with dupilumab.The Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.Noah Worcester 2024: Dr. Mesinkovska on Alopecia Areata
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-mesinkovska-alopecia-areata/24586/Natasha Atanaskova Mesinkovska. MD, PhD, summarizes her lecture on JAK inhibitors and minoxidil at the 2024 Noah Worcester Dermatological Society meeting.DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinWhat’s on the Horizon for Acne?
https://practicaldermatology.com/conferences/maui-derm-2024/whats-on-the-horizon-for-acne/20254/Julie C. Harper, MD, explains her Maui Derm presentation, including an overview of the many potential treatments for acne that are on the horizon, such as a possible acne vaccine.How Combination Treatments Can Address Unmet Needs
https://practicaldermatology.com/conferences/maui-derm-2024/how-combination-treatments-can-address-unmet-needs/20243/Suneel Chilukuri, MD, talks with Chief Medical Editor Neal Bhatia, MD, about the progress cosmetic dermatology has made to fill previous gaps in options to address areas such as the chest, neck, and knees, especially with the range of advanced devices that often produce even better results when usedHow to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.How Can Telemedicine Best Access the Inaccessible?
https://practicaldermatology.com/topics/practice-management/how-can-telemedicine-best-access-the-inaccessible/23954/Adam Friedman, MD, describes a new teledermatology program that brings care where it’s needed most.